I am a healthcare professional in the UK
I am a patient or member of the public
RaDaR Kidney Transplant CMV BTS Conference 2026 Poster
1 minute
The Impact of CMV Infection After Kidney Transplantation in the UK
Poster presented at the British Transplantation Society Conference 2026 by lead author Dr Sapna Shah (King’s College Hospital)
This poster summarises real‑world data from a UK cohort assessing the incidence, clinical features and outcomes of CMV infection after kidney transplantation. It compares refractory and non‑refractory cases, highlighting differences in presentation, treatment patterns and longer‑term outcomes such as persistent DNAemia and mortality.
This page is intended to be viewed on the large display.
The poster includes mention of maribavir
Maribavir is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT). Consideration should be given to official guidance on the appropriate use of antiviral agents.
You might be interested in
1 minute
download
This concise guide to LIVTENCITY® (maribavir) is designed for clarity and ease of use. It summarises key insights from the Phase 3 SOLSTICE trial, including efficacy outcomes, safety data, and practical dosing guidance.
article
6 minutes
A summary of the safety profile of LIVTENCITY, including adverse event data and tolerability findings from clinical studies.
article
5 minutes
Key efficacy outcomes from clinical trials evaluating LIVTENCITY in patients with post-transplant CMV, including virologic response and treatment comparisons.
article
3 minutes
CMV is one of the most common infections experienced by transplant recipients
article
4 minutes
An overview of the pivotal Phase 3 SOLSTICE trial, outlining the study design, patient population, and methodology that underpin the clinical evidence for LIVTENCITY.
